Reproductive factors and Parkinson's disease risk in Danish women

European Journal of Neurology

Volumn 21, Issue 9, 2014, Pages

  Greene, N ^a   Lassen, C F ^b   Rugbjerg, K ^b   Ritz, B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Case control studies; Parkinson's disease; Reproductive factors

Indexed keywords

CAFFEINE; ORAL CONTRACEPTIVE AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; EDUCATION; FAMILY HISTORY; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MENARCHE; PARITY; PARKINSON DISEASE; PATIENT HISTORY OF BILATERAL OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; REPRODUCTIVE HISTORY; SMOKING; AGE; DENMARK; HEALTH CARE PLANNING; MENOPAUSE; METABOLISM; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PHYSIOLOGY; REPRODUCTION; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; CONTRACEPTIVES, ORAL; DENMARK; FEMALE; HUMANS; LOGISTIC MODELS; MENARCHE; MENOPAUSE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; REPRODUCTION; RISK FACTORS;

EID: 84904977412     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12450     Document Type: Article

References (34)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-535.
2. Miller IN, Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord 2010; 25: 2695-2703.
3. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004; 75: 637-639.
4. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70: 200-209.
5. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003; 60: 790-795.
6. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001; 16: 830-837.
7. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004; 61: 886-888.
8. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005; 65: 383-390.
9. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004; 62: 2010-2014.
10. Marder K, Tang M, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 50: 1141-1143.
11. Simon K, Chen H, Gao X, Schwarzschild M, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 2009; 24: 1359-1365.
12. Ascherio A, Weisskopf M, O'Reilly E, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004; 160: 977-984.
13. Nicoletti A, Nicoletti G, Arabia G, et al. Reproductive factors and Parkinson's disease: a multicenter case-control study. Mov Disord 2011; 26: 2563-2566.
14. Rugbjerg K, Christensen J, Tjønneland A, Olsen J. Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord 2013; 19: 457-460.
15. Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL. Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol 2010; 10: 23.
16. Obata T, Kubota S. Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 2001; 308: 87-90.
17. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-268.
18. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. Dan Med Bull 2006; 53: 441-449.
19. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7 Suppl.): 38-41.
20. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10: 37-48.
21. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation and the time of hysterectomy for benign disease. Clin Obstet Gynecol 2007; 50: 354-361.
22. Stewart EA. Uterine fibroids. Lancet 2001; 357: 293-298.
23. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat Disord 2002; 8: 289-295.
24. Callier S, Morissette M, Grandbois M, Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000; 37: 245-251.
25. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997; 767: 340-344.
26. Datla K, Murray H, Pillai A, Gillies G, Dexter D. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. NeuroReport 2003; 14: 47-50.
27. Disshon KA, Dluzen DE. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res 1997; 764: 9-16.
28. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 1998; 844: 153-165.
29. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003; 110: 1215-1224.
30. Disshon KA, Boja JW, Dluzen DE. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol 1998; 345: 207-211.
31. Gaikwad NW, Murman D, Beseler CL, Zahid M, Rogan EG, Cavalieri EL. Imbalanced estrogen metabolism in the brain: possible relevance to the etiology of Parkinson's disease. Biomarkers 2011; 16: 434-444.
32. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000; 20: 8604-8609.
33. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
34. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006; 63: 584-588.